Sign In
Buy KRON
$0.88
+0 (+0%)
At Close: Sep 19, 2025
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
07:05am, Thursday, 21'st Mar 2024
Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half
How Does Kronos Stock Look After Its 15% Rise Last Week?
08:00am, Tuesday, 12'th Mar 2024
Kronos Worldwide KRO (NYSE: KRO), a titanium dioxide pigments (TiO2) producer and marketer, has gained around 15% in a week, considerably outperforming the broader Russell 2000 index which remains dow
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
04:05pm, Thursday, 07'th Mar 2024
Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
04:44pm, Tuesday, 05'th Mar 2024
SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced t
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
04:05pm, Tuesday, 27'th Feb 2024
SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced pa
Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement
08:00am, Thursday, 25'th Jan 2024
Company eliminates three executive officer roles and appoints new Executive Leadership team Company eliminates three executive officer roles and appoints new Executive Leadership team
Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development Candidate
04:06pm, Monday, 18'th Dec 2023
Phase 1b portion of phase 1b/2 lanraplenib study in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia completed; review of data does not support continuing to phase 2
Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
08:00am, Monday, 04'th Dec 2023
SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th
Kronos Bio Announces Participation in 35th Annual Piper Sandler Healthcare Conference
04:05pm, Monday, 27'th Nov 2023
SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced th
Best Penny Stocks To Buy This Week? 4 To Watch Now
10:17am, Monday, 20'th Nov 2023
Whether you're looking at the “ Magnificent Seven stocks ,” or just the next round of penny stocks to watch, news & company events can quickly sway sentiment. This week is a short holiday week wit
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Lags Revenue Estimates
06:47pm, Monday, 13'th Nov 2023
Kronos Bio, Inc. (KRON) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.57 per share a year ago.
Kronos Bio Reports Recent Business Progress and Third-Quarter 2023 Financial Results
04:05pm, Monday, 13'th Nov 2023
Company presented positive preliminary data from Phase 1 dose escalation portion of Phase 1/2 KB-0742 study at the AACR-NCI-EORTC and CTOS conferences
Strategic resource allocation to fully explore KB-0742's potential in both dose escalation and expansion cohorts across multiple tumor types in its ongoing Phase 1/2 study
Brian Van Tine, M.D., of Washington University School of Medicine, shares data from the ongoing phase 1/2 KB-0742 clinical study that clearly corresponds with the findings from the pre-clinical stud
Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting
